BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, was featured in a recent report published by Zacks Small-Cap Research. In the report, Zacks valued BVXV at $12.00/ADS. The publication reads, “On August 25, 2022, BiondVax Pharmaceuticals Ltd. (BVXV) announced financial results for the second quarter of 2022 and provided a business update. The COVID-19 NanoAb program is proceeding on schedule, with an inhalation proof-of-concept study with the anti-SARS-CoV-2 NanoAb in COVID-19 infected animals expected to begin by the end of 2022. Based on European advice the company will initiate a first-in-human phase 1/2a clinical trial in patients, thereby compressing clinical development timelines. BiondVax also recently announced that researchers at Max Planck Institute have successfully isolated NanoAbs targeting IL-17 and other cytokines, which could potentially be used to treat diseases such as psoriasis, psoriatic arthritis, asthma, and macular degeneration. BiondVax has an exclusive option for an exclusive license to develop and commercialize those drug candidates.”
To view the full report, visit https://ibn.fm/xI58S
About BiondVax Pharmaceuticals Ltd.
BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, BiondVax has executed eight clinical trials including a seven country, 12,400 participant phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
